HARBIN, China, July 5 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (OTC Bulletin Board: CSKI), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that its facilities and products passed a surprise inspection by China's State Food and Drug Administration ("SFDA") on June 28, 2007. Government officials and industry professionals working for the SFDA inspected the Company's production process, including the quality of raw materials, final packaging, consumer instructions, as well as stock-keeping methods.
Mr. Yanqing Liu, Chief Executive Officer and President of China Sky One Medical stated, "We believe that inspections like these reflect the SFDA's efforts to improve quality control and ultimately strengthen the consumer health product industry in China. We welcome such inspections and we'll continue to implement strict quality control in every step of our production process."
In order to help ensure the quality of pharmaceutical products in China, the SFDA recently started actively inspecting pharmaceutical manufacturers without notice. The SFDA inspected 30 pharmaceutical manufacturers in the Heilongjiang province, 18 of which passed the inspection and 12 of which were ordered to suspend or improve their production processes.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products in China. Through its wholly-owned subsidiaries, American California Pharmaceutical Group, Inc. ("ACPG"), Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Kangxi Medical Care Product Factory ("Kangxi"), and Harbin First Bio-Engineering Company Limited ("First"), the Company's principal revenue source is the manufacturing and sale of over-the-counter healthcare products. http://www.skyonemedical.com .
Certain of the statements made herein constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Ashley Ammon MacFarlane & Bill Zima
Integrated Corporate Relations, Inc.